News

New World Angels Leads $4MM Capital Raise for Exosome Company Aegle Therapeutics Corp.

BOCA RATON, FL (January 8, 2020) – New World Angels (NWA) (www.newworldangels.com), Florida’s premier structured angel investment group, announced today that it has completed a $790,000 investment into Aegle Therapeutics Corp. as part of a $4MM round led by NWA. NWA was joined by Tellus BioVentures, DEFTA Healthcare Technologies and DeepWork Capital, as well as existing investors including Ocean Azul Partners. The funds will support the first clinical trial in the U.S. to use exosomes as therapy.

Aegle Therapeutics Corp. is a first in class biotechnology company isolating extracellular vesicles (“EVs”) including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells as therapy. Aegle’s therapy, AGLE-102, is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder, as well as other severe dermatological conditions including
burns. Aegle has been cleared by the FDA to begin clinical studies to treat both DEB and burns. Aegle believes its technology, based on intellectual property licensed from the University of Miami and developed by Chief Science Officer, Evangelos Badiavas, MD, PhD is a platform technology with a broad range of potential indications.

Dr. David Schimel, one of NWA’s leading medical members, who will join Aegle’s Board of Directors, noted, “Aegle’s science is unique and exciting, potentially offering relief to the many children devastated by DEB and those suffering from severe burns”. Tellus BioVentures general partner, Lonnie Moulder, former CEO and co-founder of TESARO, Inc. who will also join Aegle’s board, added, “In addition to the very promising science CEO Shelley Hartman and the highly capable management team are well positioned to guide AGLE-102 through clinical trials.”

Aegle CEO Shelley Hartman commented, “We are excited to have such a high caliber of experienced investors supporting us in our ground-breaking clinical research. We expect to begin a Phase 1/2a trial in the first half of 2020 evaluating AEGL-102 in DEB.”

About New World Angels:

New World Angels (NWA) (www.newworldangels.com) is a group of 63 accredited, private investors, operators and entrepreneurs dedicated to providing equity capital and guidance to early-stage entrepreneurial companies with a strong presence in Florida. Members of NWA have extensive experience in founding, building, and managing companies in a wide variety of industries. NWA members are involved in the entrepreneurial communities from Miami to Jupiter on Florida’s east coast and from Naples to Tampa on Florida’s west coast. NWA has invested over $24MM in growing US and international companies that either are based in Florida or have a strong presence in the state. In addition to providing funding, NWA members make their expertise and resource networks available to portfolio companies to facilitate a company’s growth.

About Aegle Therapeutics
Aegle is a first in class, Boston and Miami based biotechnology company isolating extracellular vesicles
(“EVs”), including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells as therapy. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. Aegle’s IND for DEB has been cleared by the FDA and the Company expects to enter the clinic by 2H 2020.

 

MEDIA CONTACTS: New World Angels
Sarah Lucas
COO
(617) 894-5156
sarah@NewWorldAngels.com